SynthesisPharmacology research & perspectives2020
Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.
Synthesis in Pharmacology research & perspectives, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Non-genetic risk factors of miscarriage: a comprehensive umbrella review of systematic review and meta-analysis.Reproductive health · 2025Pooled it
- British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice.Rheumatology (Oxford, England) · 2023Guideline
- Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.Pharmacology research & perspectives · 2020Pooled it
- Prenatal exposure to antihypertensive medication: A systematic review of neurodevelopmental and educational outcomes.JCPP advances · 2026Article
- Important Role of Renin-Angiotensin System and Vasopressin System in Cardiovascular, Metabolic and Psychogenic Disorders in Pregnancy and Early Postnatal Life: A Narrative Review.International journal of molecular sciences · 2026Review
- A New Avenue for the Long-Term Upstream Inhibition of the Renin-Angiotensin-Aldosterone System by Inhibiting Angiotensinogen RNA.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Current Understanding on Hypertensive Disorders in Pregnancy.International journal of general medicine · 2026Review
- Prescribed medicines among pregnant women attending health facilities in Eritrea: patterns, safety, and determinants.Frontiers in pharmacology · 2026Article
- Safety profiles of cyclosporine and tacrolimus in pregnancy: a pharmacovigilance analysis using the FDA Adverse Event Reporting System.Frontiers in medicine · 2026Article
- RAAS inhibitors in pregnancy, breastfeeding and women of childbearing potential: a review of national and international clinical practice guidelines.Journal of human hypertension · 2025Review
- Medication prescribing and pregnancy-related risk factors for women with type 2 diabetes of reproductive age within primary care: a cross-sectional investigation for the PREPARED study.BMJ open diabetes research & care · 2025Article
- Article
- Preeclampsia and eclampsia: Enhanced detection and treatment for morbidity reduction.Best practice & research. Clinical anaesthesiology · 2024Review
- Fertility Management in Cystinosis: A Clinical Perspective.Kidney international reports · 2024Review
- Lupus nephritis: management challenges during pregnancy.Frontiers in nephrology · 2024Review
- Segmental low-density area on contrast-enhanced CT is a possible clue to diagnosing branch artery fibromuscular dysplasia.Endocrinology, diabetes & metabolism case reports · 2023Article
- Viral hepatitis increases the risk of cholangiocarcinoma: a systematic review and meta-analysis.Translational cancer research · 2023Article
- Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice.Rheumatology (Oxford, England) · 2023Article
- 2023 National Heart Center/Saudi Heart Association Focused Update of the 2019 Saudi Heart Association Guidelines for the Management of Heart Failure.Journal of the Saudi Heart Association · 2023Article
- Sustained activation of the renin-angiotensin-aldosteron system after fetal exposure to AT1 blockers: Effects on kidney and bone in a preterm newborn.The journal of obstetrics and gynaecology research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to determine the effects of prenatal exposure to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), particularly when exposure is limited to the first trimester of pregnancy, on adverse maternal and neonatal outcomes. A systematic search was performed on four databases, that is, PubMed, Scopus, Web of Science, and Cochrane Library, to identify relevant articles published up to December 31, 2019. Included studies were limited to original investigations assessing the association between prenatal exposure to ACEIs/ARBs and adverse pregnancy outcomes. Odds ratios were used as a summary effect measure. Pooled-effect estimates of each outcome were calculated by the random-effects meta-analysis. The main outcomes included overall and specific congenital malformations, low birth weight, miscarriage, elective termination of pregnancy, stillbirth, and preterm delivery. Of 19 included articles involving a total of 4 163 753 pregnant women, 13 studies reported an increased risk of, at least, one adverse pregnancy outcome in pregnant women who were exposed to ACEIs/ARBs. Meta-analysis revealed a significant association between overall congenital malformations and first trimester-only exposure to ACEIs/ARBs (OR = 1.94, 95% CI = 1.71-2.21, P < .0001). Cardiovascular malformations, miscarriage, and stillbirth also provided a significant relation with ACEI/ARB exposure. In conclusion, prenatal exposure to ACEIs/ARBs in the first trimester of pregnancy was found to be associated with an increased risk of adverse pregnancy outcomes. Women of reproductive age should be aware of the potential teratogenic risks of these drugs if they become pregnant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.